https://orcid.org/0000-0001-8019-9811
References
- Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997;25(8):970–977.
- Clinical Pharmacogenomics Implementation Consortium (CPIC) [Internet]. 2020. https://cpicpgx.org/
- Mulder TAM, van Eerden RAG, de With M, et al. CYP3A4 (*)22 genotyping in clinical practice: ready for implementation? Front Genet. 2021;12:711943.
- Deodhar M, Rihani SBA, Darakjian L, et al. Assessing the mechanism of Fluoxetine-Mediated CYP2D6 inhibition. Pharmaceutics. 2021;13(2):148.
- Doohan PT, Oldfield LD, Arnold JC, et al. Cannabinoid interactions with cytochrome P450 drug metabolism: a Full-Spectrum characterization. Aaps J. 2021;23(4):91.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.